Matthias Scheffler
Matthias Scheffler is an expert in Oncology at University Hospital Cologne (Germany). As of October 2026, ScienceLeadR ranks Matthias Scheffler in the top 1% of experts worldwide for Bronchial Neoplasms, Lung Neoplasms and Thoracic Neoplasms. Matthias Scheffler has authored 176 publications, the most recent in 2026, and is an investigator in 10 clinical trials, 5 of them ongoing. SLR score: 769 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pulmonology - Genetics - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 176
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass). PMID 42710416 — cells, genes, recombination, genetic, lung, poly(adp-ribose) polymerases, homologous recombination, neoplasms, poly adenosine diphosphate ribose, biomarkers, maintenance, lung neoplasms, recombinational dna repair, small cell lung carcinoma, therapeutics, etoposide, carboplatin | Clin Lung Cancer | 2026 | 0 |
| FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC. PMID 42848441 — cells, safety, neoplasms, carcinoma, non-small-cell lung, mutation | Clin Cancer Res | 2026 | 0 |
| Response to Trastuzumab Deruxtecan in a Patient With EGFR-Mutated NSCLC and Transformation to SCLC Harboring HER2 Amplification: A Case Report. PMID 42657058 — carcinoma, non-small-cell lung, trastuzumab | JTO Clin Res Rep | 2026 | 0 |
| Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses. PMID 42268349 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy | Clin Cancer Res | 2026 | 0 |
| First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. PMID 41985129 — cells, epidermal growth factor, lung, growth, progression-free survival, brain, neoplasms, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, lung neoplasms, neoplasm metastasis, receptors, growth factor, small cell lung carcinoma, therapeutics | N Engl J Med Top journal | 2026 | 0 |
Clinical Studies 10
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Beamion LUNG 3 A study to test whether zongertinib helps people with surgically removed non small cell lung cancer with HER2 mutations compared with standard treatment 2025-521284-12-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation | Phase 3 | Not yet recruiting | 2026 |
| Beamion 44 A study to test how well zongertinib is tolerated by people with advanced non small cell lung cancer with HER2 mutations when given in combination with chemotherapy with or without pembrolizumab 2025-523567-38-00 — cells, lung, safety, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy, her2 mutation | Phase 2 | Recruiting | 2026 |
| BEAMION Lung 2 A study to test whether zongertinib (BI 1810631) helps people with advanced non small cell lung cancer with HER2 mutations compared with standard treatment 2023-504308-27-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation | Phase 3 | Active not recruiting | 2024 |
| Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet) NCT05818449 — depression, cells, quality of life, lung, patient participation, genetics, hospitals, private, neoplasms, pathology, pathology, molecular, carcinoma, non-small-cell lung, documentation, private practice, lung neoplasms, small cell lung carcinoma, physicians, database management systems, precision medicine, diagnosis, patient reported outcome measures, hospitals, community, therapeutics, counseling, genomic medicine, carcinoma | N/A | Active not recruiting | 2022 |
| Beamion LUNG 1 A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) NCT04886804 — cells, genes, lung, genes, erbb-2, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, therapeutics, carcinoma | Phase 1 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map